CClinicalTrials.gg
CompletedNCT02302261Updated Jul 26, 2016

Pleth Variability and Asthma Severity in Children

An observational study in Status Asthmaticus, sponsored by Northwell Health. Completed at 1 site in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-26.

Sponsored by Northwell Health · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
37
Ages
Up to 17 Years
Sex
All
01

Study summary

Research has shown that pleth variability can be used to assess asthma severity in children with status asthmaticus. The investigators would like to use an FDA-cleared monitor (Masimo Radical 7) which measures Pleth Variability Index (PVI) to see if the degree of PVI can be used to help triage patients who present to the pediatric ED in status asthmaticus.

Read the detailed description

Patients with asthma have obstruction to exhalation resulting in hyperinflation of their lungs. This hyperinflation results in a phenomenon known as pulsus paradoxus in which the physiologic drop in blood pressure normally seen with inhalation is exaggerated. Studies have shown that patients with more severe asthma exacerbations (i.e. more hyperinflation) have a greater degree of pulsus paradoxus. Typically, pulsus paradoxus is measured using a sphygmomanometer, however, researchers have demonstrated that it can also accurately be measured using plethysmography, a term known as pleth variability index (PVI). Using this concept, Arnold et al (2008, 2010) showed that a greater degree of pulsus paradoxus correlates with asthma severity.

The investigators' study aims to simplify the association between PVI and asthma severity. The investigators hypothesize the following:

  1. Patients with a higher admission PVI will have a higher likelihood of being admitted to the hospital.
  2. Patients admitted to the Intensive Care Unit (PICU) will have a higher PVI than patients admitted to a floor.
  3. PVI can be accurately used to gauge response to bronchodilator/anti-inflammatory therapy.
  4. PVI is as effective as respiratory severity score in predicting asthma severity and in gauging response to bronchodilator therapy.

To do this the investigators will recruit children who present to the pediatric ED in status asthmaticus. They will be connected to a Masimo Radical 7 monitor upon admission to the ED and then again 4 hours later. In addition the investigators will calculate respiratory severity scores at those same time intervals. The investigators will then look at the disposition of the patient upon leaving the ED: discharge to home, admission to an inpatient floor or admission to the ICU.

02

Conditions studied

  • Status Asthmaticus

Browse trials for

Keywords

  • Pulsus paradoxus
03

In context

Status Asthmaticus

39 studies on the registry are indexed under Status Asthmaticus; 2 are open to participants now.

Browse Status Asthmaticus studies →

Lead sponsor

Northwell Health is the lead sponsor of 463 studies on the registry; 109 are open to participants now.

Of its 40 completed or terminated interventional studies of FDA-regulated products, 20 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We will study patients who present to the pediatric ED at Cohen Children's Medical Center of NY with status asthmaticus.

Inclusion criteria

  • Diagnosis of asthma or reactive airway disease upon leaving the ED
  • Greater than 10 kg

Exclusion criteria

Exclusion Criteria:

  • Patients in whom effective pulse oximetry tracings cannot be obtained
  • Patients who are diagnosed with conditions other than asthma/reactive airway disease that are known to cause pulsus paradoxus
05

Study design

Time perspective
Prospective
Enrollment
37 participants (actual)
Patient registry
No

Groups and cohorts

  • Status Asthmaticus

    Any patient presenting to the ED with status asthmaticus.

06

What researchers measure

Primary outcomes

  1. Disposition from ED

    Determine whether a patient was discharged from the ED, admitted to an inpatient floor or admitted to the ICU.

    Time frame: 4 hours

Secondary outcomes

  1. Comparison to respiratory severity score

    Is PVI as effective as RSS in determining asthma severity

    Time frame: 4 hours

  2. Change in disposition within 24 hours

    Determine if a patient who was discharged home from the ED required readmission to the ED within 1 week. Determine if a patient admitted to the floor or ICU required a change in level of care in the first 24 hours of admission.

    Time frame: 1 week

07

Study locations

1 site
  • Cohen Children's Medical Center of NY
    New Hyde Park, New York 11040, United States
08

References and documents

Publications

  • Arnold DH, Gebretsadik T, Minton PA, Higgins S, Hartert TV. Assessment of severity measures for acute asthma outcomes: a first step in developing an asthma clinical prediction rule. Am J Emerg Med. 2008 May;26(4):473-9. doi: 10.1016/j.ajem.2007.05.026. PubMed 18410819 ↗
  • Arnold DH, Jenkins CA, Hartert TV. Noninvasive assessment of asthma severity using pulse oximeter plethysmograph estimate of pulsus paradoxus physiology. BMC Pulm Med. 2010 Mar 29;10:17. doi: 10.1186/1471-2466-10-17. PubMed 20350320 ↗
  • Cannesson M, Desebbe O, Rosamel P, Delannoy B, Robin J, Bastien O, Lehot JJ. Pleth variability index to monitor the respiratory variations in the pulse oximeter plethysmographic waveform amplitude and predict fluid responsiveness in the operating theatre. Br J Anaesth. 2008 Aug;101(2):200-6. doi: 10.1093/bja/aen133. Epub 2008 Jun 2. PubMed 18522935 ↗
  • Clark JA, Lieh-Lai M, Thomas R, Raghavan K, Sarnaik AP. Comparison of traditional and plethysmographic methods for measuring pulsus paradoxus. Arch Pediatr Adolesc Med. 2004 Jan;158(1):48-51. doi: 10.1001/archpedi.158.1.48. PubMed 14706958 ↗
  • Frey B, Freezer N. Diagnostic value and pathophysiologic basis of pulsus paradoxus in infants and children with respiratory disease. Pediatr Pulmonol. 2001 Feb;31(2):138-43. doi: 10.1002/1099-0496(200102)31:23.0.co;2-r. PubMed 11180690 ↗
  • Rayner J, Trespalacios F, Machan J, Potluri V, Brown G, Quattrucci LM, Jay GD. Continuous noninvasive measurement of pulsus paradoxus complements medical decision making in assessment of acute asthma severity. Chest. 2006 Sep;130(3):754-65. doi: 10.1378/chest.130.3.754. PubMed 16963672 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02302261
Lead sponsor
Northwell Health
Collaborators
Masimo Corporation
Responsible party
Ariel Brandwein (Pediatric Critical Care Fellow, Northwell Health) — Principal investigator
First posted
Nov 26, 2014
Start date
Jan 2015
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Jul 26, 2016

Study contacts

Ariel Brandwein, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion